AVEMAR (a new benzoquinone-containing natural product) administration interferes with the Th2 response in experimental SLE and promotes amelioration of the disease
Restricted accessResearch articleFirst published online September, 2001
AVEMAR (a new benzoquinone-containing natural product) administration interferes with the Th2 response in experimental SLE and promotes amelioration of the disease
The potential of oral treatment with AVEMAR (AVEMAR), a new benzoquinone-containing fermentation product of wheat germ, on features of experimental systemic lupus erythematosus (SLE) in naive mice, induced by idiotypic manipulation, was studied. We assessed the effect of AVEMAR on the profile of autoantibody production and the response of Th1=Th2 related cytokines as well as the clinical picture of experimental SLE in the SLE-induced mice.
When the product was given in the pre-immunization period, down-regulation of autoantibody production (anti-dsDNA, mouse 16=6 Id, and anti-histones) following treatment with AVEMAR was noted (eg anti-dsDNA decreased from 0.898 0.097 OD at 405 nm to 0.519 0.103 OD following treatment). This effect was sustained for at least 4 weeks after discontinuation of the therapy. Serological manifestations associated with a delay in Th2 response (IL-4 and IL-10) were recorded (eg IL-4 decreased from 91.7 8.11 to 59.55 7.78 ng =ml in splenocyte condition media). The mice showed normal ESR, WBC and less than 100 mg/dl of protein in the urine in comparison to > 300 mg/dl protein in the SLE non-treated mice.
In conclusion, oral intake of AVEMAR can ameliorate the clinical manifestations of experimental SLE, via affecting the Th1=Th2 network inhibiting Th2 response.
Shoenfeld Y.Idiotypic induction of autoimmunity: a new aspect of the idiotypic network . FASEB J1994; 8: 1296–1301 .
2.
Mendelovic S , Brocke S , Shoenfeld Y et al. Induction of a SLE-like disease in mice by a common anti-DNA idiotype . Proc Natl Acad Sci USA1988; 85: 2260–2264 .
3.
Blank M , Mendelovic S , Mozes E et al. Induction of SLE-like disease in naive mice with a monoclonal anti-DNA antibody derived from a patient with polymyositis carrying 16=6 Id . J Autoimmun1988; 1: 683–691 .
4.
Tincani A , Balesterieri G , Allegri F et al. Induction of experimental SLE in naive mice by immunization with human polyclonal anti-DNA antibody carrying the 16=6 idiotype . Clin Exp Rheumatol1994; 11: 129–134 .
5.
Shoenfeld Y , Mozes E.Pathogenic idiotypes of antibodies and auto-immunity: a lesson from a new syndrome of experimental SLE . FASEB J1990; 4: 2646–2651 .
6.
Rombach E , Stetler DA , Brown JC.Rabbits produce SLE-like anti-RNA polymerase I and anti-DNA autoantibodies in responses to immunization with either human or murine SLE anti-DNA antibodies . Autoimmunity1992; 13: 291–302 .
7.
Bakimer R , Fishman P , Blank M et al. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anti-cardiolipin antibody (H-3) . J Clin Invest1992; 89: 1558–1663 .
8.
Blank M , Tomer Y , Stein M et al. Immunization with anti-neutrophil cytoplasmic antibody (ANCA) induces the production of mouse ANCA and perivascular lymphocyte infiltration . Clin Exp Immunol1995; 102: 120–129 .
9.
Segal R , Bermas BL , Dayan M , Kalush F , Shearer GM , Mozes E.Kinetics of cytokine production in experimental systemic lupus erythematosus: involvement of T helper cell 1=T helper cell 2-type cytokines in disease . J Immunol1997; 158: 3009–3016 .
10.
Krause I , Blank M , Levi Y , Koike T , Barak V , Shoenfeld Y.Anti-idiotype immunomodulation of experimental anti-phospholipid syndrome via effect on Th1=Th2 expression . Clin Exp Immunol1999; 117: 190–197 .
11.
Shoenfeld Y.Immunosuppression of experimental systemic lupus erythematosus and antiphospholipid syndrome . Transplant Proc1994; 26: 3211–3215 .
12.
Krause I , Blank M , Shoenfeld Y.Treatment of systemic lupus erythematosus and antiphospholipid syndrome: from experimental models to patients' bedside . Int Arch Allergy Immunol1996; 111: 355–361 .
13.
Shoenfeld Y , Krause I.Immunosuppression and immunomodulation of experimental models of systemic lupus erythematosus and antiphospholipid syndrome . Transplant Proc1996; 28: 3096–3098 .
14.
Shoenfeld Y , Krause I , Blank M.New methods of treatment in an experimental murine model of systemic lupus erythematosus induced by idiotypic manipulation . Ann Rheum Dis1997; 56: 5–11 .
15.
Reifen R , Blank M , Afek A et al. Dietary polyunsaturated fatty acids decrease anti-dsDNA and anti-cardiolipin antibodies production in idiotype induced mouse model of systemic lupus erythematosus . Lupus1998; 7: 192–197 .
16.
Reifen R , Amital H , Blank M , Sklan D , Berkovich Z , Gershwin E , Shoenfeld Y.Linseed oil suppresses the anti-beta-2-glycoprotein-I in experimental antiphospholipid syndrome . J Autoimmun2000; 15: 381–385 .
17.
Szent-Györgyi A.Metabolism and cancer . Int J Quantum Chem Quantum Biol Symp1985; 12: 257–261 .
18.
Hidvegi M , Raso E , Tomoskozi-Farkas R , Paku S , Lapis K , Szende B.Effect of Avemar and Avemar / vitamin C on tumor growth and metastasis in experimental animals . Anticancer Res1998; 18: 2353–2358 .
19.
Hidvegi M , Raso E , Tomoskozi-Farkas R et al. AVEMAR, a new benzoquinone-containing natural product with antimetastatic effect . Cancer Biother Radiopharm1999; 14: 277–289 .
20.
Hidvegi M , Raso E , Tomoskozi-Farkas R , Lapis K , Szende B.Effect of AVEMAR on the immune response of mice . Immunopharmacology1999; 41: 183–186 .
21.
Erickson KL , Hubbard NE , Somers SD.Dietary fat and immune function. In: Chandra RK (ed). Nutrition and Immunity. Arts Biomedical Publishers: St John's, Newfoundland , 1992, pp 81–104.
22.
Gershwin ME , Lentz DR , Beach RS , Hurley LS.Nutritional factors and autoimmunity . IV. Dietary vitamin A deprivation induces a selective increase in IgM autoantibodies and hypergammaglobulinemia in New Zealand Black mice. J Immunol1984; 133: 222–226 .
23.
Yumura W , Hattori S , Morrow WJ , Mayes DC , Levy JA , Shirai T.Dietary fat and immune function. II. Effects on immune complex nephritis in (NZB × NZW)F1 mice . J Immunol1985; 135: 3864–3868 .
24.
Lim BO , Jolly CA , Zaman K , Fernandes G.Dietary (n-6) and (n-3) fatty acids and energy restriction modulate mesenteric lymph node lymphocyte function in autoimmune-prone (NZB × NZW)F1 mice . J Nutr2000; 130: 1657–1664 .
25.
Wu WM , Chiang BL , Chang SC , Lin BF.Late feeding of dietary fish oil alleviates disease severity and affects macrophage function in autoimmune NZB/W F1 mice . J Microbiol Immunol Infect2000; 33: 79–86 .
26.
Shigemasa C , Tanaka T , Mashiba H.Effect of vegetarian diet on systemic lupus erythematosus . Lancet1992; 339(8802): 1177-1177 .
27.
Walton AJ , Snaith ML , Locniskar M , Cumberland AG , Morrow WJ , Isenberg DA.Dietary fish oil and the severity of symptoms in patients with systemic lupus erythematosus . Ann Rheum Dis1991; 50: 463–466 .
28.
Thorner A , Walldius G , Nilsson E , Hadell K , Gullberg R.Beneficial effects of reduced intake of polyunsaturated fatty acids in the diet for one year in patients with systemic lupus erythematosus . Ann Rheum Dis1990; 49: 134-134 .
29.
Nicholson LB , Kuchroo VK.Manipulation of the Th1=Th2 balance in autoimmune disease . Curr Opin Immunol1996; 8: 837–842 .
30.
Peng SL , Moslehi J , Craft J.Roles of interferon-gamma and inter-leukin-4 in murine lupus . J Clin Invest1997; 99: 1936–1946 .
31.
Nakajima A , Hirose S , Yagita H , Okumura K.Roles of IL-4 and IL-12 in the development of lupus in NZB/W F1 mice . J Immunol1997; 158: 1466–1472 .
32.
Ruger BM , Erb KJ , He Y , Lane JM , Davis PF , Hasan Q.Interleukin-4 transgenic mice develop glomerulosclerosis independent of immuno-globulin deposition . Eur J Immunol2000; 30: 2698–2703 .
33.
Jolly CA , Fernandes G.Diet modulates Th-1 and Th-2 cytokine production in the peripheral blood of lupus-prone mice . J Clin Immunol1999; 19: 172–178 .
34.
Richaud-Patin Y , Alcocer-Varela J , Llorente L.High levels of TH2 cytokine gene expression in systemic lupus erythematosus . Rev Invest Clin1995; 47: 267–272 .
35.
Llorente L , Richaud-Patin Y , Fior R et al. In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjogren's syndrome, and systemic lupus erythematosus. A potential mechanism of B lymphocyte hyperactivity and autoimmunity . Arthrit Rheum1994; 37: 1647–1655 .
36.
Hagiwara E , Gourley MF , Lee S , Klinman DK.Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10: interferon-gamma-secreting cells in the peripheral blood . Arthrit Rheum1996; 39: 379–385 .
37.
Horwitz DA , Gray JD , Behrendsen SC et al. Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus . Arthrit Rheum1998; 41: 838–844 .
38.
Lacki JK , Samborski W , Mackiewicz SH.Interleukin-10 and inter-leukin-6 in lupus erythematosus and rheumatoid arthritis, correlations with acute phase proteins . Clin Rheumatol1997; 16: 275–278 .
39.
Houssiau FA , Lefebvre C , Vanden Berghe M , Lambert M , Devogelaer JP , Renauld JC.Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity . Lupus1995; 4: 393–395 .
40.
Park YB , Lee SK , Kim DS , Lee J , Lee CH , Song CH.Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus . Clin Exp Rheumatol1998; 16: 283–288 .
41.
Llorente L , Richaud-Patin Y , Garcia-Padilla C et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus . Arthrit Rheum2000; 43: 1790–1800 .
42.
Prud'homme GJ.Gene therapy of autoimmune diseases with vectors encoding regulatory cytokines or inflammatory cytokine inhibitors . J Gene Med2000; 2: 222–232 .
